What is Syndax Pharmaceuticals Inc Annual Net Profit?

Syndax Pharmaceuticals Inc Annual Net Profit fell 52.25% in the last year to $318.76 M. Its sector's average net profit growth for the last fiscal year was -32.45%.

What is Syndax Pharmaceuticals Inc Price to Earning Ratio?

Syndax Pharmaceuticals Inc Price to Earning Ratio is -3.54, which is negative.

What is Syndax Pharmaceuticals Inc Stock Price?

Syndax Pharmaceuticals Inc Stock Price fell 40.15% and underperformed its sector by 49.82% in the past year.

What is Syndax Pharmaceuticals Inc Quarterly Net profit?

Syndax Pharmaceuticals Inc Quarterly Net profit fell 29.94% YoY to $94.17 M. Its sector's average net profit growth YoY for the quarter was -47.5%.

What is Syndax Pharmaceuticals Inc Mutual Fund Holding?

Syndax Pharmaceuticals Inc Mutual Fund Holding decreased by 1.11% in the last quarter to 42.26.

What is Syndax Pharmaceuticals Inc Promoter Share Holding?

Syndax Pharmaceuticals Inc Promoter Share Holding increased by 1.38% in the most recent quarter to 3.75%.

What is Syndax Pharmaceuticals Inc Institutional Holding?

Syndax Pharmaceuticals Inc Institutional Holding remained the same in the last quarter at 114.68%.

How is the Syndax Pharmaceuticals Inc today?

The Syndax Pharmaceuticals Inc today is trading in the green, up by 4.04% at 13.12.

How has Syndax Pharmaceuticals Inc performed historically?

The Syndax Pharmaceuticals Inc is currently trading up 4.04% on an intraday basis in the past week the index rose 0.92%. The index has been down -0.91% in the past quarter and fell -40.15% in the past year. You can view this in the overview section.

Syndax Pharmaceuticals Inc XNAS: SNDX

Syndax Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

Name: Syndax Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Syndax Pharmaceuticals Inc
Rating: 0.93733325
Author: Trendlyne DVM scores

Download real time

13.12 0.51 (4.04%)

47.67% Fall from 52W High

1.2M XNAS Volume

XNAS 19 Mar, 2025 5:30 PM (EDT)

Syndax Pharmaceuticals Inc Key Metrics

My Metrics

Select

Market Capitalization High in industry Unavailable in chosen country	1,128.6
PE TTM Negative PE TTM Unavailable in chosen country	-3.5
PEG TTM Below industry Median Unavailable in chosen country	0.1
Price to Book Below industry Median Unavailable in chosen country	3.1
Institutional holding current Qtr % High in industry Unavailable in chosen country	114.7
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-29.9
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-52.3
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-1,434.4
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-8.2

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

8.8 / 100

Technically Bearish

28.7 / 100

1Yr Price target upside is 175%

14 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Syndax Pharmaceuticals Inc Stock Price Analysis

Day Price Range 4.0% 1 Day return Unavailable in chosen country	13.1 (LTP) 12.413.2 LowHigh
Week Price Range 0.9% 1 Week return Unavailable in chosen country	13.1 (LTP) 12.413.5 LowHigh
Month Price Range -10.3% 1 Month return Unavailable in chosen country	13.1 (LTP) 12.317 LowHigh
52 Week Price Range -40.2% 1 Year return Unavailable in chosen country	13.1 (LTP) 12.125.1 LowHigh

View full Share Price History

Syndax Pharmaceuticals Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Syndax Pharmaceuticals Inc's Revenue was lower than average estimate 1 time in past 1 year

EPS forecast

QUARTER
ANNUAL

Current EPS

-3.7

Avg. Estimate

-3.9

Low Estimate

-4.6

High Estimate

-2.6

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 3.8% in FY25

Consensus Recommendation

15 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 15 analysts for Syndax Pharmaceuticals Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Syndax Pharmaceuticals Inc Stock Analysis

Syndax Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Syndax Pharmaceuticals Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$318.76 M	52.25%	negative	Annual Net Profit fell 52.25% in the last year to $318.76 M. Its sector's average net profit growth for the last fiscal year was -32.45%.
Price to Earning Ratio	-3.54	-	negative	Price to Earning Ratio is -3.54, which is negative.
Stock Price	$13.12	-40.15%	negative	Stock Price fell 40.15% and underperformed its sector by 49.82% in the past year.
Quarterly Net profit	$94.17 M	29.94%	negative	Quarterly Net profit fell 29.94% YoY to $94.17 M. Its sector's average net profit growth YoY for the quarter was -47.5%.
Mutual Fund Holding	42.26 %	-1.11%	negative	Mutual Fund Holding decreased by 1.11% in the last quarter to 42.26.
Promoter Share Holding	3.75 %	1.38%	positive	Promoter Share Holding increased by 1.38% in the most recent quarter to 3.75%.
Institutional Holding	114.68 %	0%	neutral	Institutional Holding remained the same in the last quarter at 114.68%.

VIEW LESS

Loading data..

Syndax Pharmaceuticals Inc - Company Profile

What does Syndax Pharmaceuticals Inc do?

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Gross Remuneration

2024

Gross Remuneration

Year

Syndax Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

47.67% Fall from 52W High

Syndax Pharmaceuticals Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Syndax Pharmaceuticals Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Syndax Pharmaceuticals Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Syndax Pharmaceuticals Inc's Revenue was lower than average estimate 1 time in past 1 year

EPS forecast

EPS is expected to reduce by 3.8% in FY25

Consensus Recommendation

The consensus recommendation from 15 analysts for Syndax Pharmaceuticals Inc is STRONG BUY

Syndax Pharmaceuticals Inc Stock Analysis

Syndax Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 52.25% in the last year to $318.76 M. Its sector's average net profit growth for the last fiscal year was -32.45%.

Price to Earning Ratio is -3.54, which is negative.

Stock Price fell 40.15% and underperformed its sector by 49.82% in the past year.

Quarterly Net profit fell 29.94% YoY to $94.17 M. Its sector's average net profit growth YoY for the quarter was -47.5%.

Mutual Fund Holding decreased by 1.11% in the last quarter to 42.26.

Promoter Share Holding increased by 1.38% in the most recent quarter to 3.75%.

Institutional Holding remained the same in the last quarter at 114.68%.

Syndax Pharmaceuticals Inc - Company Profile

What does Syndax Pharmaceuticals Inc do?

Syndax Pharmaceuticals Inc Management structure

Mr. Steve M. Sabus

Chief Commercial Officer

Mr. Steven Closter

Chief Commercial Officer

Ms. Catherine Madigan

Chief Medical Officer

Mr. Michael A. Metzger

Director and Chief Executive Officer

Mr. Keith A. Goldan

Chief Financial Officer and Principal Accounting Officer

Syndax Pharmaceuticals Inc Board of directors

Dr. Briggs W. Morrison, M.D.

Director

Dr. Aleksandra Rizo, M.D.,PhD

Director

Mr. Dennis G. Podlesak

Chairman of the Board

Mr. Keith A. Katkin

Independent Director

Mr. Pierre Legault, C.P.A.,M.B.A.

Independent Director

Mr. Michael A. Metzger

Director and Chief Executive Officer

Syndax Pharmaceuticals Inc FAQ

How is Syndax Pharmaceuticals Inc today?

Syndax Pharmaceuticals Inc today is trading in the green, and is up by 4.04% at 13.12.

How has Syndax Pharmaceuticals Inc performed historically?

Syndax Pharmaceuticals Inc is currently trading up 4.04% on an intraday basis. In the past week the stock rose 0.92%. stock has been down -0.91% in the past quarter and fell -40.15% in the past year. You can view this in the overview section.